Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors

A systematic review of randomized controlled trials

Ausilia Maione, Sankar D. Navaneethan, Giusi Graziano, Ruth Mitchell, David Johnson, Johannes F E Mann, Peggy Gao, Jonathan C. Craig, Giovanni Tognoni, Vlado Perkovic, Antonio Nicolucci, Salvatore De Cosmo, Antonio Sasso, Olga Lamacchia, Mauro Cignarelli, Valeria Maria Manfreda, Giorgio Gentile, Giovanni F M Strippoli

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background. A recent clinical trial showed harmful renal effects with the combined use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) in people with diabetes or vascular disease. We examined the benefits and risks of these agents in people with albuminuria and one or more cardiovascular risk factors.Methods. MEDLINE, EMBASE and Renal Health Library were searched for trials comparing ACEI, ARB or their combination with placebo or with one another in people with albuminuria and one or more cardiovascular risk factor.Results. Eighty-five trials (21 708 patients) were included. There was no significant reduction in the risk of all-cause mortality or fatal cardiac-cerebrovascular outcomes with ACEI versus placebo, ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI + ARB versus monotherapy. There was a significant reduction in the risk of nonfatal cardiovascular events with ACEI versus placebo but not with ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI + ARB versus monotherapy. Development of end-stage kidney disease and progression of microalbuminuria to macroalbuminuria were reduced significantly with ACEI versus placebo and ARB versus placebo but not with combined therapy with ACEI + ARB versus monotherapy.Conclusions. ACEI and ARB exert independent renal and nonfatal cardiovascular benefits while their effects on mortality and fatal cardiovascular disease are uncertain. There is a lack of evidence to support the use of combination therapy. A comparative clinical trial with ACE, ARB and its combination in people with albuminuria and a cardiovascular risk factor is warranted.

Original languageEnglish
Pages (from-to)2827-2847
Number of pages21
JournalNephrology Dialysis Transplantation
Volume26
Issue number9
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Randomized Controlled Trials
Placebos
Albuminuria
Therapeutics
Risk Reduction Behavior
Kidney
Clinical Trials
Mortality
Vascular Diseases
MEDLINE
Libraries
Chronic Kidney Failure
Disease Progression
Cardiovascular Diseases

Keywords

  • angiotensin receptor blockers
  • angiotensin-converting enzyme inhibitors
  • macroalbuminuria
  • microalbuminuria

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors : A systematic review of randomized controlled trials. / Maione, Ausilia; Navaneethan, Sankar D.; Graziano, Giusi; Mitchell, Ruth; Johnson, David; Mann, Johannes F E; Gao, Peggy; Craig, Jonathan C.; Tognoni, Giovanni; Perkovic, Vlado; Nicolucci, Antonio; De Cosmo, Salvatore; Sasso, Antonio; Lamacchia, Olga; Cignarelli, Mauro; Maria Manfreda, Valeria; Gentile, Giorgio; Strippoli, Giovanni F M.

In: Nephrology Dialysis Transplantation, Vol. 26, No. 9, 09.2011, p. 2827-2847.

Research output: Contribution to journalArticle

Maione, A, Navaneethan, SD, Graziano, G, Mitchell, R, Johnson, D, Mann, JFE, Gao, P, Craig, JC, Tognoni, G, Perkovic, V, Nicolucci, A, De Cosmo, S, Sasso, A, Lamacchia, O, Cignarelli, M, Maria Manfreda, V, Gentile, G & Strippoli, GFM 2011, 'Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors: A systematic review of randomized controlled trials', Nephrology Dialysis Transplantation, vol. 26, no. 9, pp. 2827-2847. https://doi.org/10.1093/ndt/gfq792
Maione, Ausilia ; Navaneethan, Sankar D. ; Graziano, Giusi ; Mitchell, Ruth ; Johnson, David ; Mann, Johannes F E ; Gao, Peggy ; Craig, Jonathan C. ; Tognoni, Giovanni ; Perkovic, Vlado ; Nicolucci, Antonio ; De Cosmo, Salvatore ; Sasso, Antonio ; Lamacchia, Olga ; Cignarelli, Mauro ; Maria Manfreda, Valeria ; Gentile, Giorgio ; Strippoli, Giovanni F M. / Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors : A systematic review of randomized controlled trials. In: Nephrology Dialysis Transplantation. 2011 ; Vol. 26, No. 9. pp. 2827-2847.
@article{2ac2e8369f1e40bda708eeffa9a3960a,
title = "Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors: A systematic review of randomized controlled trials",
abstract = "Background. A recent clinical trial showed harmful renal effects with the combined use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) in people with diabetes or vascular disease. We examined the benefits and risks of these agents in people with albuminuria and one or more cardiovascular risk factors.Methods. MEDLINE, EMBASE and Renal Health Library were searched for trials comparing ACEI, ARB or their combination with placebo or with one another in people with albuminuria and one or more cardiovascular risk factor.Results. Eighty-five trials (21 708 patients) were included. There was no significant reduction in the risk of all-cause mortality or fatal cardiac-cerebrovascular outcomes with ACEI versus placebo, ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI + ARB versus monotherapy. There was a significant reduction in the risk of nonfatal cardiovascular events with ACEI versus placebo but not with ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI + ARB versus monotherapy. Development of end-stage kidney disease and progression of microalbuminuria to macroalbuminuria were reduced significantly with ACEI versus placebo and ARB versus placebo but not with combined therapy with ACEI + ARB versus monotherapy.Conclusions. ACEI and ARB exert independent renal and nonfatal cardiovascular benefits while their effects on mortality and fatal cardiovascular disease are uncertain. There is a lack of evidence to support the use of combination therapy. A comparative clinical trial with ACE, ARB and its combination in people with albuminuria and a cardiovascular risk factor is warranted.",
keywords = "angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, macroalbuminuria, microalbuminuria",
author = "Ausilia Maione and Navaneethan, {Sankar D.} and Giusi Graziano and Ruth Mitchell and David Johnson and Mann, {Johannes F E} and Peggy Gao and Craig, {Jonathan C.} and Giovanni Tognoni and Vlado Perkovic and Antonio Nicolucci and {De Cosmo}, Salvatore and Antonio Sasso and Olga Lamacchia and Mauro Cignarelli and {Maria Manfreda}, Valeria and Giorgio Gentile and Strippoli, {Giovanni F M}",
year = "2011",
month = "9",
doi = "10.1093/ndt/gfq792",
language = "English",
volume = "26",
pages = "2827--2847",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors

T2 - A systematic review of randomized controlled trials

AU - Maione, Ausilia

AU - Navaneethan, Sankar D.

AU - Graziano, Giusi

AU - Mitchell, Ruth

AU - Johnson, David

AU - Mann, Johannes F E

AU - Gao, Peggy

AU - Craig, Jonathan C.

AU - Tognoni, Giovanni

AU - Perkovic, Vlado

AU - Nicolucci, Antonio

AU - De Cosmo, Salvatore

AU - Sasso, Antonio

AU - Lamacchia, Olga

AU - Cignarelli, Mauro

AU - Maria Manfreda, Valeria

AU - Gentile, Giorgio

AU - Strippoli, Giovanni F M

PY - 2011/9

Y1 - 2011/9

N2 - Background. A recent clinical trial showed harmful renal effects with the combined use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) in people with diabetes or vascular disease. We examined the benefits and risks of these agents in people with albuminuria and one or more cardiovascular risk factors.Methods. MEDLINE, EMBASE and Renal Health Library were searched for trials comparing ACEI, ARB or their combination with placebo or with one another in people with albuminuria and one or more cardiovascular risk factor.Results. Eighty-five trials (21 708 patients) were included. There was no significant reduction in the risk of all-cause mortality or fatal cardiac-cerebrovascular outcomes with ACEI versus placebo, ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI + ARB versus monotherapy. There was a significant reduction in the risk of nonfatal cardiovascular events with ACEI versus placebo but not with ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI + ARB versus monotherapy. Development of end-stage kidney disease and progression of microalbuminuria to macroalbuminuria were reduced significantly with ACEI versus placebo and ARB versus placebo but not with combined therapy with ACEI + ARB versus monotherapy.Conclusions. ACEI and ARB exert independent renal and nonfatal cardiovascular benefits while their effects on mortality and fatal cardiovascular disease are uncertain. There is a lack of evidence to support the use of combination therapy. A comparative clinical trial with ACE, ARB and its combination in people with albuminuria and a cardiovascular risk factor is warranted.

AB - Background. A recent clinical trial showed harmful renal effects with the combined use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) in people with diabetes or vascular disease. We examined the benefits and risks of these agents in people with albuminuria and one or more cardiovascular risk factors.Methods. MEDLINE, EMBASE and Renal Health Library were searched for trials comparing ACEI, ARB or their combination with placebo or with one another in people with albuminuria and one or more cardiovascular risk factor.Results. Eighty-five trials (21 708 patients) were included. There was no significant reduction in the risk of all-cause mortality or fatal cardiac-cerebrovascular outcomes with ACEI versus placebo, ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI + ARB versus monotherapy. There was a significant reduction in the risk of nonfatal cardiovascular events with ACEI versus placebo but not with ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI + ARB versus monotherapy. Development of end-stage kidney disease and progression of microalbuminuria to macroalbuminuria were reduced significantly with ACEI versus placebo and ARB versus placebo but not with combined therapy with ACEI + ARB versus monotherapy.Conclusions. ACEI and ARB exert independent renal and nonfatal cardiovascular benefits while their effects on mortality and fatal cardiovascular disease are uncertain. There is a lack of evidence to support the use of combination therapy. A comparative clinical trial with ACE, ARB and its combination in people with albuminuria and a cardiovascular risk factor is warranted.

KW - angiotensin receptor blockers

KW - angiotensin-converting enzyme inhibitors

KW - macroalbuminuria

KW - microalbuminuria

UR - http://www.scopus.com/inward/record.url?scp=79959866121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959866121&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfq792

DO - 10.1093/ndt/gfq792

M3 - Article

VL - 26

SP - 2827

EP - 2847

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 9

ER -